Current Drugs with Potential for Treatment of COVID-19: A Literature Review.
Identifieur interne : 000232 ( Main/Exploration ); précédent : 000231; suivant : 000233Current Drugs with Potential for Treatment of COVID-19: A Literature Review.
Auteurs : Md Insiat Islam Rabby [Malaisie]Source :
- Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques [ 1482-1826 ] ; 2020.
Descripteurs français
- KwdFr :
- MESH :
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Anti-inflammatoires, Antipaludiques, Antiviraux.
- Animaux, Humains, Médecine traditionnelle chinoise, Pandémies.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Anti-Inflammatory Agents, Antimalarials, Antiviral Agents.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- Animals, Betacoronavirus, Humans, Medicine, Chinese Traditional, Pandemics.
Abstract
SARS-CoV-2 first emerged in China in December 2019 and rapidly spread worldwide. No vaccine or approved drug is available to eradicate the virus, however, some drugs that are indicated for other afflictions seems to be potentially beneficial to treat the infection albeit without unequivocal evidence. The aim of this article is to review the published background on the effectiveness of these drugs against COVID-19 Methods: A thorough literature search was conducted on recently published studies which have published between January 1 to March 25, 2020. PubMed, Google Scholar and Science Direct databases were searched Results: A total 22 articles were found eligible. 8 discuss about treatment outcomes from their applied drugs during treatment of COVID-19 patients, 4 report laboratory tests, one report animal trial and other 9 articles discuss recommendations and suggestions based on the treatment process and clinical outcomes of other diseases such as malaria, ebola, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). The data and/or recommendations are categorized in 4 classes: (a) anti-viral and anti-inflammatory drugs, (b) anti-malaria drugs, (c) traditional Chinese drugs and (d) other treatments/drugs.
DOI: 10.18433/jpps31002
PubMed: 32251618
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000084
- to stream PubMed, to step Curation: 000084
- to stream PubMed, to step Checkpoint: 000239
- to stream Ncbi, to step Merge: 002705
- to stream Ncbi, to step Curation: 002705
- to stream Ncbi, to step Checkpoint: 002705
- to stream Main, to step Merge: 000235
- to stream Main, to step Curation: 000232
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Current Drugs with Potential for Treatment of COVID-19: A Literature Review.</title><author><name sortKey="Md Insiat Islam Rabby" sort="Md Insiat Islam Rabby" uniqKey="Md Insiat Islam Rabby" last="Md Insiat Islam Rabby">Md Insiat Islam Rabby</name><affiliation wicri:level="1"><nlm:affiliation>Department of Mechanical and Manufacturing Engineering, Universiti Putra Malaysia, Malaysia.</nlm:affiliation><country xml:lang="fr">Malaisie</country><wicri:regionArea>Department of Mechanical and Manufacturing Engineering, Universiti Putra Malaysia</wicri:regionArea><wicri:noRegion>Universiti Putra Malaysia</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32251618</idno><idno type="pmid">32251618</idno><idno type="doi">10.18433/jpps31002</idno><idno type="wicri:Area/PubMed/Corpus">000084</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000084</idno><idno type="wicri:Area/PubMed/Curation">000084</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000084</idno><idno type="wicri:Area/PubMed/Checkpoint">000239</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000239</idno><idno type="wicri:Area/Ncbi/Merge">002705</idno><idno type="wicri:Area/Ncbi/Curation">002705</idno><idno type="wicri:Area/Ncbi/Checkpoint">002705</idno><idno type="wicri:Area/Main/Merge">000235</idno><idno type="wicri:Area/Main/Curation">000232</idno><idno type="wicri:Area/Main/Exploration">000232</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Current Drugs with Potential for Treatment of COVID-19: A Literature Review.</title><author><name sortKey="Md Insiat Islam Rabby" sort="Md Insiat Islam Rabby" uniqKey="Md Insiat Islam Rabby" last="Md Insiat Islam Rabby">Md Insiat Islam Rabby</name><affiliation wicri:level="1"><nlm:affiliation>Department of Mechanical and Manufacturing Engineering, Universiti Putra Malaysia, Malaysia.</nlm:affiliation><country xml:lang="fr">Malaisie</country><wicri:regionArea>Department of Mechanical and Manufacturing Engineering, Universiti Putra Malaysia</wicri:regionArea><wicri:noRegion>Universiti Putra Malaysia</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques</title><idno type="eISSN">1482-1826</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Anti-Inflammatory Agents (therapeutic use)</term><term>Antimalarials (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus</term><term>Coronavirus Infections (drug therapy)</term><term>Humans</term><term>Medicine, Chinese Traditional</term><term>Pandemics</term><term>Pneumonia, Viral (drug therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anti-inflammatoires (usage thérapeutique)</term><term>Antipaludiques (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Humains</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Médecine traditionnelle chinoise</term><term>Pandémies</term><term>Pneumopathie virale (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Antimalarials</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anti-inflammatoires</term><term>Antipaludiques</term><term>Antiviraux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Betacoronavirus</term><term>Humans</term><term>Medicine, Chinese Traditional</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Médecine traditionnelle chinoise</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">SARS-CoV-2 first emerged in China in December 2019 and rapidly spread worldwide. No vaccine or approved drug is available to eradicate the virus, however, some drugs that are indicated for other afflictions seems to be potentially beneficial to treat the infection albeit without unequivocal evidence. The aim of this article is to review the published background on the effectiveness of these drugs against COVID-19 Methods: A thorough literature search was conducted on recently published studies which have published between January 1 to March 25, 2020. PubMed, Google Scholar and Science Direct databases were searched Results: A total 22 articles were found eligible. 8 discuss about treatment outcomes from their applied drugs during treatment of COVID-19 patients, 4 report laboratory tests, one report animal trial and other 9 articles discuss recommendations and suggestions based on the treatment process and clinical outcomes of other diseases such as malaria, ebola, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). The data and/or recommendations are categorized in 4 classes: (a) anti-viral and anti-inflammatory drugs, (b) anti-malaria drugs, (c) traditional Chinese drugs and (d) other treatments/drugs.</div></front></TEI><affiliations><list><country><li>Malaisie</li></country></list><tree><country name="Malaisie"><noRegion><name sortKey="Md Insiat Islam Rabby" sort="Md Insiat Islam Rabby" uniqKey="Md Insiat Islam Rabby" last="Md Insiat Islam Rabby">Md Insiat Islam Rabby</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000232 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000232 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32251618
|texte= Current Drugs with Potential for Treatment of COVID-19: A Literature Review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32251618" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |